<p>随着美国股市在符合预期的通胀数据发布后上涨，投资者正密切关注各个行业的机会。尽管通常被视为过去交易日的遗物，便士股今天依然相关，因为它们在较低的价格点提供潜在的增长机会。本文探讨了三只展现财务实力和稳定性的有前景的便士股，为投资者提供了发掘优质公司隐藏价值的机会。</p>
<h3>美国十大便士股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.10</td>
<td>$447.9M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.99</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$5.00</td>
<td>$56.92M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Puma Biotechnology (PBYI)</td>
<td>$4.70</td>
<td>$237.75M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Sensus Healthcare (SRTS)</td>
<td>$3.13</td>
<td>$51.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.99</td>
<td>$25.49M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Table Trac (TBTC)</td>
<td>$4.50</td>
<td>$21.81M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9962</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$87M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股筛选器的 375 只股票的完整列表。</p>
<p>下面我们重点介绍几只我们独家的筛选器中的最爱。</p>
<h2>Zenvia (ZENV)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Zenvia Inc. 运营一个基于云的平台，提供跨多个国家的集成通信解决方案，市值为 7531 万美元。</p>
<p><strong>运营：</strong> 公司通过两个主要部门产生收入：SaaS，贡献 3.2522 亿雷亚尔，和 CPaaS，贡献 7.7232 亿雷亚尔。</p>
<p><strong>市值：</strong> $75.31M</p>
<p>Zenvia Inc. 的市值为 7531 万美元，运营于基于云的通信领域，展现出来自其 SaaS 和 CPaaS 部门的有前景的收入来源。尽管在 2025 年第二季度报告了 4198 万雷亚尔的净亏损，但它通过在五年内将债务与股本比率从 75.5% 降低到 12.5%，并保持正的自由现金流，现金流持续超过三年，改善了其财务状况。然而，挑战依然存在，因为短期负债超过资产，且收益波动性持续高于行业标准，尽管过去一年每周波动性稳定。</p>
<ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Zenvia 的表现。</li>
<li>通过我们的公司收益预估报告，获取 Zenvia 的前景和预期表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 ZENV 的债务与股本历史及分析</p>
<h2>Nautilus Biotechnology (NAUT)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家开发阶段的生命科学公司，专注于创建一个平台技术，以量化和理解蛋白质组的复杂性，市值为 9095 万美元。</p>
<p><strong>运营：</strong> 作为一家开发阶段的公司，Nautilus Biotechnology 尚未报告任何收入部门。</p>
<p><strong>市值：</strong> $90.95M</p>
<p>Nautilus Biotechnology 的市值为 9095 万美元，仍处于无收入阶段，专注于开发蛋白质组分析技术。尽管在 2025 年第二季度报告了 1503 万美元的净亏损和上半年的 3165 万美元净亏损，但其财务健康状况因短期资产（1.507 亿美元）超过负债且无债务而得到增强。该公司最近与艾伦研究所建立了战略联盟，以探索 tau 蛋白在阿尔茨海默病进展中的作用，尽管预计未来三年收益将下降，现金流即使按历史速度减少，现金流也将持续超过两年。</p>
<ul>
<li>在我们的财务健康报告中更详细地了解 Nautilus Biotechnology 的潜力。</li>
<li>通过查看我们的增长报告，获取 Nautilus Biotechnology 未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 NAUT 的债务与股本历史及分析</p>
<h2>Prelude Therapeutics (PRLD)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家临床阶段的精准肿瘤学公司，致力于为服务不足的患者发现和开发新型癌症药物，市值为 6905 万美元。</p>
<p><strong>运营：</strong> Prelude Therapeutics 目前未报告任何收入部门。</p>
<p><strong>市值：</strong> $69.05M</p>
<p>Prelude Therapeutics 的市值为 6905 万美元，处于无收入阶段，专注于开发精准肿瘤学治疗。该公司在 2025 年第二季度报告了 3123 万美元的净亏损，较去年同期的 3474 万美元亏损有所改善，表明在管理费用方面略有进展。Prelude 保持无债务，短期资产（7690 万美元）超过负债，但如果当前现金流趋势持续，现金流将不足一年。尽管股价波动性高，预计未来三年收益将下降，但其经验丰富的管理层和董事会在财务不确定性中提供了一定的稳定性。</p>
<ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 Prelude Therapeutics 的动态。</li>
<li>在这里了解 Prelude Therapeutics 未来的增长轨迹。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 PRLD 的债务与股本历史及分析</p>
<h2>将想法转化为行动</h2>
<ul>
<li>点击这里访问我们完整的 375 只美国便士股票索引。</li>
<li>准备好采取不同的方法了吗？这 13 家公司在 COVID 之后生存并蓬勃发展，具备应对特朗普关税的正确要素。在您的投资组合感受到贸易战的压力之前，了解原因。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

PRLD

ZENV

NAUT

<p>美国股市正在上涨，激发了对低价股的兴趣，这些股票在较低价格下提供增长潜力。本文重点介绍了三只有前景的低价股：Zenvia Inc.（市值 7531 万美元）、Nautilus Biotechnology（市值 9095 万美元）和 Prelude Therapeutics（市值 6905 万美元）。尽管 Zenvia 出现了净亏损，但其财务状况有所改善；Nautilus 尚未产生收入，但无债务且拥有大量短期资产；Prelude 同样尚未产生收入，但在管理费用方面略有改善。每家公司为投资者提供了独特的机会和挑战</p>

<p>As the U.S. stock market experiences a rise following inflation data that met expectations, investors are keenly watching for opportunities across various sectors. Though often seen as relics of past trading days, penny stocks remain relevant today by offering potential growth at lower price points. In this article, we explore three promising penny stocks that showcase financial strength and stability, providing investors with the opportunity to uncover hidden value in quality companies.</p>
<div class="lb-trans"><p>随着美国股市在符合预期的通胀数据发布后上涨，投资者正密切关注各个行业的机会。尽管通常被视为过去交易日的遗物，便士股今天依然相关，因为它们在较低的价格点提供潜在的增长机会。本文探讨了三只展现财务实力和稳定性的有前景的便士股，为投资者提供了发掘优质公司隐藏价值的机会。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.10</td>
<td>$447.9M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.99</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$5.00</td>
<td>$56.92M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Puma Biotechnology (PBYI)</td>
<td>$4.70</td>
<td>$237.75M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Sensus Healthcare (SRTS)</td>
<td>$3.13</td>
<td>$51.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.99</td>
<td>$25.49M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Table Trac (TBTC)</td>
<td>$4.50</td>
<td>$21.81M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9962</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$87M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.10</td>
<td>$447.9M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.99</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Global Self Storage (SELF)</td>
<td>$5.00</td>
<td>$56.92M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Puma Biotechnology (PBYI)</td>
<td>$4.70</td>
<td>$237.75M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Sensus Healthcare (SRTS)</td>
<td>$3.13</td>
<td>$51.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.99</td>
<td>$25.49M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Table Trac (TBTC)</td>
<td>$4.50</td>
<td>$21.81M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9962</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$87M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 375 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股筛选器的 375 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我们重点介绍几只我们独家的筛选器中的最爱。</p>
</div><h2>Zenvia (ZENV)</h2>
<div class="lb-trans"><h2>Zenvia (ZENV)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Zenvia Inc. operates a cloud-based platform facilitating integrated communication solutions across multiple countries, with a market cap of $75.31 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Zenvia Inc. 运营一个基于云的平台，提供跨多个国家的集成通信解决方案，市值为 7531 万美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through two primary segments: SaaS, contributing R$325.22 million, and CPaaS, accounting for R$772.32 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司通过两个主要部门产生收入：SaaS，贡献 3.2522 亿雷亚尔，和 CPaaS，贡献 7.7232 亿雷亚尔。</p>
</div><p><strong>Market Cap:</strong> $75.31M</p>
<div class="lb-trans"><p><strong>市值：</strong> $75.31M</p>
</div><p>Zenvia Inc., with a market cap of $75.31 million, operates in the cloud-based communication sector, showing promising revenue streams from its SaaS and CPaaS segments. Despite reporting a net loss of BRL 41.98 million for Q2 2025, it has improved its financial position over time by reducing its debt to equity ratio from 75.5% to 12.5% in five years and maintaining a positive free cash flow with a cash runway exceeding three years. However, challenges remain as short-term liabilities surpass assets and earnings volatility persists above industry norms despite stable weekly volatility over the past year.</p>
<div class="lb-trans"><p>Zenvia Inc. 的市值为 7531 万美元，运营于基于云的通信领域，展现出来自其 SaaS 和 CPaaS 部门的有前景的收入来源。尽管在 2025 年第二季度报告了 4198 万雷亚尔的净亏损，但它通过在五年内将债务与股本比率从 75.5% 降低到 12.5%，并保持正的自由现金流，现金流持续超过三年，改善了其财务状况。然而，挑战依然存在，因为短期负债超过资产，且收益波动性持续高于行业标准，尽管过去一年每周波动性稳定。</p>
</div><ul>
<li>Get an in-depth perspective on Zenvia's performance by reading our balance sheet health report here.</li>
<li>Gain insights into Zenvia's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Zenvia 的表现。</li>
<li>通过我们的公司收益预估报告，获取 Zenvia 的前景和预期表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a988ca80-4990-44b9-a618-35582349ddb7/chart/debt-equity-history-analysis"/></p>
<p>ZENV Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 ZENV 的债务与股本历史及分析</p>
</div><h2>Nautilus Biotechnology (NAUT)</h2>
<div class="lb-trans"><h2>Nautilus Biotechnology (NAUT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and understand the complexity of the proteome, with a market cap of $90.95 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家开发阶段的生命科学公司，专注于创建一个平台技术，以量化和理解蛋白质组的复杂性，市值为 9095 万美元。</p>
</div><p><strong>Operations:</strong> As a development stage company, Nautilus Biotechnology has not yet reported any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> 作为一家开发阶段的公司，Nautilus Biotechnology 尚未报告任何收入部门。</p>
</div><p><strong>Market Cap:</strong> $90.95M</p>
<div class="lb-trans"><p><strong>市值：</strong> $90.95M</p>
</div><p>Nautilus Biotechnology, with a market cap of US$90.95 million, remains pre-revenue, focusing on developing proteome analysis technology. Despite reporting net losses of US$15.03 million for Q2 2025 and US$31.65 million for the first half of the year, its financial health is bolstered by substantial short-term assets (US$150.7M) exceeding liabilities and being debt-free. The company recently entered a strategic alliance with the Allen Institute to explore tau proteins' role in Alzheimer's disease progression, highlighting potential scientific breakthroughs despite projected earnings declines over the next three years and a cash runway extending over two years even if cash flow reduces at historical rates.</p>
<div class="lb-trans"><p>Nautilus Biotechnology 的市值为 9095 万美元，仍处于无收入阶段，专注于开发蛋白质组分析技术。尽管在 2025 年第二季度报告了 1503 万美元的净亏损和上半年的 3165 万美元净亏损，但其财务健康状况因短期资产（1.507 亿美元）超过负债且无债务而得到增强。该公司最近与艾伦研究所建立了战略联盟，以探索 tau 蛋白在阿尔茨海默病进展中的作用，尽管预计未来三年收益将下降，现金流即使按历史速度减少，现金流也将持续超过两年。</p>
</div><ul>
<li>Take a closer look at Nautilus Biotechnology's potential here in our financial health report.</li>
<li>Gain insights into Nautilus Biotechnology's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更详细地了解 Nautilus Biotechnology 的潜力。</li>
<li>通过查看我们的增长报告，获取 Nautilus Biotechnology 未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>NAUT Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 NAUT 的债务与股本历史及分析</p>
</div><h2>Prelude Therapeutics (PRLD)</h2>
<div class="lb-trans"><h2>Prelude Therapeutics (PRLD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $69.05 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家临床阶段的精准肿瘤学公司，致力于为服务不足的患者发现和开发新型癌症药物，市值为 6905 万美元。</p>
</div><p><strong>Operations:</strong> Prelude Therapeutics does not currently report any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Prelude Therapeutics 目前未报告任何收入部门。</p>
</div><p><strong>Market Cap:</strong> $69.05M</p>
<div class="lb-trans"><p><strong>市值：</strong> $69.05M</p>
</div><p>Prelude Therapeutics, with a market cap of US$69.05 million, is pre-revenue and focused on developing precision oncology treatments. The company reported a net loss of US$31.23 million for Q2 2025, an improvement from the previous year's loss of US$34.74 million, indicating slight progress in managing expenses. Prelude remains debt-free with short-term assets (US$76.9M) exceeding liabilities, but faces challenges with less than a year of cash runway if current cash flow trends persist. Despite high share price volatility and forecasted earnings declines over the next three years, its experienced management and board offer some stability amidst financial uncertainties.</p>
<div class="lb-trans"><p>Prelude Therapeutics 的市值为 6905 万美元，处于无收入阶段，专注于开发精准肿瘤学治疗。该公司在 2025 年第二季度报告了 3123 万美元的净亏损，较去年同期的 3474 万美元亏损有所改善，表明在管理费用方面略有进展。Prelude 保持无债务，短期资产（7690 万美元）超过负债，但如果当前现金流趋势持续，现金流将不足一年。尽管股价波动性高，预计未来三年收益将下降，但其经验丰富的管理层和董事会在财务不确定性中提供了一定的稳定性。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of Prelude Therapeutics.</li>
<li>Learn about Prelude Therapeutics' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 Prelude Therapeutics 的动态。</li>
<li>在这里了解 Prelude Therapeutics 未来的增长轨迹。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>PRLD Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 PRLD 的债务与股本历史及分析</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>将想法转化为行动</h2>
</div><ul>
<li>Click here to access our complete index of 375 US Penny Stocks.</li>
<li>Ready For A Different Approach? These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的 375 只美国便士股票索引。</li>
<li>准备好采取不同的方法了吗？这 13 家公司在 COVID 之后生存并蓬勃发展，具备应对特朗普关税的正确要素。在您的投资组合感受到贸易战的压力之前，了解原因。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

3 只市值超过 6000 万美元的有潜力的便士股